<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136448</url>
  </required_header>
  <id_info>
    <org_study_id>92-148</org_study_id>
    <nct_id>NCT00136448</nct_id>
  </id_info>
  <brief_title>High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)</brief_title>
  <official_title>High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      This study will add interleukin-2 (IL-2) to a regimen of post-remission therapy consisting of&#xD;
      high-dose ara-C. Patients with AML in first remission will receive 3 cycles of high-dose&#xD;
      ara-C followed by continuous infusion and bolus interleukin-2 (IL-2). We, the researchers at&#xD;
      the Dana-Farber Cancer Institute, plan to evaluate the immunologic effects of such treatment&#xD;
      in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive standard remission induction therapy with daunorubicin at a dose of 45&#xD;
      mg/m2/day for 3 days and continuous infusion cytarabine at a dose of 200 mg/m2/day for 7&#xD;
      days.&#xD;
&#xD;
      Those patients who enter a remission status and have preserved liver and kidney function will&#xD;
      then receive 3 cycles of post-remission therapy that will consist of high-dose cytarabine at&#xD;
      a dose of 3000 mg/m2 every 12 (q12) hours on days 1, 3 and 5 (total of 6 doses).&#xD;
&#xD;
      Patients who are still in remission will receive interleukin-2 (IL-2) upon count recovery at&#xD;
      a dose of 8.1 X 10^5 U/m2/day by continuous infusion for 10 weeks. In addition, patients will&#xD;
      receive bolus IL-2 at a dose of 6 X 10^5 U/m2 by intravenous bolus weekly for 6 doses through&#xD;
      day 63.&#xD;
&#xD;
      Patients will be seen on a weekly basis while on treatment for examination and bloodwork.&#xD;
&#xD;
      At the end of treatment, patients will have a physical exam and bloodwork performed monthly&#xD;
      for two years, then 4 times per year for two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1993</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary purpose of this study is to evaluate the ability of IL-2 to generate cytotoxic and inhibitory activity against cryopreserved autologous leukemic myeloblasts obtained at the time of diagnosis.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of continuous infusion IL-2 with intermittent IL-2 boluses in patients with AML who have received 3 cycles of post-remission intensification therapy with high-dose ara-C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess additional immunologic effects of IL-2</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To obtain preliminary data regarding the rate of disease relapse</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytosine arabinoside (ara-C)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunomycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interleukin-2</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have AML based on French-American-British (FAB) criteria.&#xD;
&#xD;
          -  Patients must have a total bilirubin of &lt; 2.0 mg/dL, SGOT &lt; 90 IU/mL, alkaline&#xD;
             phosphatase &lt; 250 U/mL and a serum creatinine &lt; 2.0 mg/dL.&#xD;
&#xD;
          -  Age 18 years or greater.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of an antecedent hematologic malignancy such as myelodysplastic syndromes&#xD;
             (MDS).&#xD;
&#xD;
          -  Uncontrolled infection.&#xD;
&#xD;
          -  History of a previous or concomitant malignancy other than non-melanoma skin cancer.&#xD;
&#xD;
          -  Evidence of central nervous system (CNS) leukemia.&#xD;
&#xD;
          -  Current use of corticosteroids.&#xD;
&#xD;
          -  Prior treatment for AML, other than hydroxyurea.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M. Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <keyword>AML</keyword>
  <keyword>acute myelogenous leukemia</keyword>
  <keyword>cytarabine</keyword>
  <keyword>interleukin-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

